PMID- 34699003
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20211111
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 38
IP  - 12
DP  - 2021 Dec
TI  - Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of 
      Eosinophilic Esophagitis: A Cost-Utility Analysis.
PG  - 5737-5751
LID - 10.1007/s12325-021-01957-7 [doi]
AB  - INTRODUCTION: Budesonide orodispersible tablets (BOT) have been approved in 
      Europe and Canada for the treatment of eosinophilic esophagitis (EoE), a rare and 
      chronic disease. The objective of this study was to assess the economic impact of 
      BOT on both the induction and maintenance of clinico-pathological remission of 
      EoE by performing a cost-utility analysis (CUA). METHODS: For both the induction 
      and maintenance settings, BOT was compared to no treatment in a target population 
      of adult patients with EoE non-responsive to proton pump inhibitor (PPI) 
      treatment. Markov models were developed for the induction and maintenance 
      settings over 52-week and life-time horizons, respectively. Analyses were 
      performed from both a Canadian Ministry of Health (MoH) and societal perspective. 
      The resulting incremental cost-utility ratios (ICURs) were compared to a 
      willingness-to-pay (WTP) threshold of $50,000 Canadian dollars/quality-adjusted 
      life-year (QALY). Sensitivity and scenario analyses were conducted to assess the 
      robustness of the base-case results. RESULTS: In the base-case probabilistic 
      analysis, BOT compared to no treatment resulted in an ICUR of $1073/QALY and 
      $30,555/QALY from a MoH perspective in the induction and maintenance settings, 
      respectively. BOT was a cost-effective option for both induction and maintenance 
      in > 99% of Monte Carlo simulations. In the scenario analyses, the deterministic 
      ICUR of BOT compared to no treatment varied from $682/QALY to $8510/QALY in the 
      induction setting and $21,005/QALY to $55,157/QALY in the maintenance setting. 
      CONCLUSION: BOT was cost-effective compared to no treatment for both the 
      induction and maintenance of clinico-pathological remission of EoE in patients 
      non-responsive to PPIs.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Beauchemin, C
AU  - Beauchemin C
AUID- ORCID: 0000-0002-5903-5430
AD  - PeriPharm Inc., 485 McGill St. Suite 910, Montreal, QC, H2Y 2H4, Canada. 
      catherine.beauchemin@peripharm.com.
AD  - University of Montreal, Montreal, QC, Canada. catherine.beauchemin@peripharm.com.
FAU - Castonguay, A
AU  - Castonguay A
AD  - PeriPharm Inc., 485 McGill St. Suite 910, Montreal, QC, H2Y 2H4, Canada.
FAU - Chan, E S
AU  - Chan ES
AD  - Division of Allergy and Immunology, Department of Pediatrics, British Columbia 
      Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
FAU - Dellon, E S
AU  - Dellon ES
AD  - Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and 
      Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC, 
      USA.
AD  - Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology 
      and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, 
      USA.
FAU - Feagan, B G
AU  - Feagan BG
AD  - Department of Medicine, Western University, London, ON, Canada.
AD  - London Health Sciences Centre, London, ON, Canada.
AD  - Alimentiv Inc., London, ON, Canada.
FAU - Ma, C
AU  - Ma C
AD  - Alimentiv Inc., London, ON, Canada.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, University 
      of Calgary, Calgary, AB, Canada.
AD  - Division of Gastroenterology and Hepatology, Department of Community Health 
      Sciences, University of Calgary, Calgary, AB, Canada.
FAU - Waserman, S
AU  - Waserman S
AD  - Division of Allergy and Clinical Immunology, Department of Medicine, McMaster 
      University, Hamilton, ON, Canada.
FAU - Cook, J
AU  - Cook J
AD  - CHEORS, North Wales, PA, USA.
FAU - Claveau, D
AU  - Claveau D
AD  - AVIR Pharma Inc., Blainville, QC, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211026
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Tablets)
RN  - 51333-22-3 (Budesonide)
MH  - Adult
MH  - *Budesonide
MH  - Canada
MH  - Cost-Benefit Analysis
MH  - *Eosinophilic Esophagitis/drug therapy
MH  - Humans
MH  - Quality-Adjusted Life Years
MH  - Tablets
OTO - NOTNLM
OT  - Budesonide orodispersible tablets
OT  - Cost-effective
OT  - Cost-utility
OT  - Economic evaluation
OT  - Eosinophilic esophagitis
EDAT- 2021/10/27 06:00
MHDA- 2021/11/12 06:00
CRDT- 2021/10/26 12:35
PHST- 2021/08/26 00:00 [received]
PHST- 2021/10/08 00:00 [accepted]
PHST- 2021/10/27 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2021/10/26 12:35 [entrez]
AID - 10.1007/s12325-021-01957-7 [pii]
AID - 10.1007/s12325-021-01957-7 [doi]
PST - ppublish
SO  - Adv Ther. 2021 Dec;38(12):5737-5751. doi: 10.1007/s12325-021-01957-7. Epub 2021 
      Oct 26.